MedDRA Term Selection: Latest activities of the Points to Consider Working Group

Similar documents
Use of MedDRA in Special Situations

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

Frequently Asked Questions

Medication Errors a challenge of pharmacovigilance BfArM experience

PHARMACOVIGILANCE GLOSSARY

Proposed MedDRA Version 17.0 Complex Changes (July 2013)

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski

Data retrieval using the new SMQ Medication Errors

MedDRA Overview A Standardized Terminology

MedDRA TERM SELECTION: POINTS TO CONSIDER

Advanced MedDRA Coding

What s New MedDRA Version March

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA Basic Concept

Pharmacovigilance Methods and Post-Authorisation Safety Studies

Session 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016

Navigating the Table of Drugs & Chemicals

MedDRA Coding Quality: How to Avoid Common Pitfalls

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

Other EU Activities Contributing to Harmonization of Labeling

MedDRA TERM SELECTION: POINTS TO CONSIDER

Coding with MedDRA 4/22/2015

PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

What Medical Writers Need to Know About MedDRA

Coding with MedDRA 3/2/2017

Introduction to MedDRA

Minister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018

MedDRA Coding and Versioning

Re: Non-prescription availability of low-dose codeine products

Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA

MedDRA TERM SELECTION: POINTS TO CONSIDER

Coding with Confidence

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

What s New MedDRA Version 13.1

Ontario s Narcotics Strategy

I am pleased to highlight for this Honourable House and the public. that today the Government will be laying amendments to the

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

MedDRA - International standard for coding safety information. The Golden Triangle

Routine signal detection and statistical tools on paediatrics

Applies to: Signal and Incident Management Service in the Inspections, Human Medicines Pharmacovigilance and Committees division

Regulatory Aspects of Pharmacovigilance

Coding with MedDRA 1

Q&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Coding with MedDRA 1

NEWSLETTER October The Pharmacovigilance Risk Assessment Committee July (PRAC) Meeting

Coding with MedDRA 3/6/2019

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program

What s New MedDRA Version 18.0

MARYLAND BOARD OF PHARMACY

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 December 2007

How to change the legal classification of a medicine in New Zealand

Challenges in Conducting Postmarketing Abuse Investigations

Changing practice to support service delivery

Safety Data Analysis and Query Creation with MedDRA

Washington State PMP Data Mapping Project

Strengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018

Existing WHO work on Medicines Safety & Safe Use. Department of Essential Medicines and Health Products World Health Organization

Quality, Safety and Sourcing in Unlicensed Medicines

The Home Office Proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 January 2018

Key points. o Potential for nonmedical use, abuse, and diversion of new products

Implemented MedDRA Version 22.0 Complex Changes (October 2018)

Ref: E 007. PGEU Response. Consultation on measures for improving the recognition of medical prescriptions issued in another Member State

What s New MedDRA Version March

POISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes

PRAC recommendations on signals

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Shining a Light on MEDs Understanding morphine equivalent dose

BRIEF: Why are we making these changes?

Why pay for Continuing Education when you can get it for FREE!?

Chapter 6 PHARMACOVIGELANCE. M.G.Rajanandh, Department of Pharmacy Practice, SRM College of Pharmacy, SRM University.

6/6/2017. First Do No Harm SECTION 1 THE OPIOID CRISIS. Implementing an Opioid Stewardship Program in a HealthCare System OBJECTIVES

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

Navigating Pain Management during the Opioid Epidemic: Focus Group Findings

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference

NALOXONE RISK ASSESSMENT

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

SCDSW5 Manage ethical issues, dilemmas and conflicts

Switzerland - still a special country?

Medicaid and the Opioid Crisis

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

The Impact of the Opioid Crisis. Deborah A. McMahan, MD Health Commissioner Allen County Department of Health

TITLE: SAFE USE OF MEDICINES IN ZANZIBAR A

Medicinal product no longer authorised

Safe Prescribing and Dispensing of Controlled Drugs. Joint Guidance Medical Council and Pharmaceutical Society of Ireland

Naloxone and Combating the Opioid Epidemic

Community Pharmacists' Attitudes toward the safety of deregulated medicines

Holders of European Union marketing authorizations

MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Evaluating the Impact of Abuse Deterrent Formulations: Methodological Challenges in Postmarketing Data

Data Analysis and Query Building with MedDRA

RADARS R SYSTEM INTERNATIONAL PRE-SYMPOSIUM. International Landscape of Prescription Medication Misuse

Synopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)

Access to newly licensed medicines. Scottish Medicines Consortium

SFHAB2 - SQA Unit Code HG0T 04 Support individuals who misuse substances

Increase in Opioid Related Deaths What the Data Can Tell us. Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes

Transcription:

MedDRA Term Selection: Latest activities of the Points to Consider Working Group Patrick Revelle MedDRA MSSO 23 May 2013 Overview The new EU pharmacovigilance legislation broadened the definition of an adverse event Now includes terms in MedDRA for off label use, overdose, misuse, abuse, medication errors, and occupational exposure MedDRA Term Selection: Points to Consider (MTS:PTC) document changed as a result Drug Information Association www.diahome.org 2 1

EU Pharmacovigilance Directive Chapter 17 Member States should operate a pharmacovigilance system to collect information that is useful for the monitoring of medicinal products, including information on suspected adverse reactions arising from use of a medicinal product within the terms of the marketing authorisation as well as from use outside the terms of the marketing authorisation, including overdose, misuse, abuse and medication errors, and suspected adverse reactions associated with occupational exposure. Drug Information Association www.diahome.org 3 MedDRA PTC Documents There are two PTC documents Term Selection Data Retrieval and Presentation Using MedDRA is a big step forward Using MedDRA the same way is a leap toward harmonization Drug Information Association www.diahome.org 4 2

Revisions Related to New EU PV Legislation Significant revisions to MedDRA Term Selection: Points to Consider for Release 4.5, based on MedDRA v16.0 Definitions added (consistent with international regulatory authorities definitions) Examples added New section on Misuse, Abuse and Addiction MedDRA Introductory Guide v16.0 Definitions added MedDRA v16.0 (March 2013) Added new HLT Occupational exposures Drug Information Association www.diahome.org 5 Off Label Use Terms in MedDRA Currently in MedDRA Drug Information Association www.diahome.org 6 3

Off Label Use MTS:PTC (1) 3.27 Off Label Use Relates to situations where the product is intentionally used for a medical purpose not in accordance with the authorized product information Reported as an indication Reported with an AR/AE Drug Information Association www.diahome.org 7 Off Label Use MTS:PTC (2) Reported as an indication Medical condition reported as an indication along with off label use Preferred option is to select terms for the medical condition and LLT Off label use Alternatively, select a term for the medical condition/indication alone. Select LLT Off label use alone only if it is the only information available. Drug Information Association www.diahome.org 8 4

Off Label Use MTS:PTC (3) Reported with an AR/AE Preferred option is to select LLT Off label use and a term for the medical condition in addition to a term for the AR/AE Alternatively, select a term for the medical condition and a term for the AR/AE Drug Information Association www.diahome.org 9 Overdose Terms in MedDRA (1) Current Overdose terms in MedDRA Drug Information Association www.diahome.org 10 5

Overdose EMA Definition Overdose This refers to the administration of a quantity of a medicinal product given per administration or cumulatively, which is above the maximum recommended dose according to the authorised product information. Clinical judgement should always be applied. EMA. Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products. Drug Information Association www.diahome.org 11 Overdose MTS:PTC 3.18 Overdose, Toxicity and Poisoning If overdose, poisoning or toxicity is explicitly reported, select the appropriate term. Guidance provided for cases with and without clinical consequences Drug Information Association www.diahome.org 12 6

Misuse, Abuse and Addiction New MTS:PTC section 3.16 Misuse, Abuse and Addiction Closely related and can pose challenges for coding given overlap in meaning PTC includes a table to help provide guidance based on several factors Drug Information Association www.diahome.org 13 Misuse Terms in MedDRA Current Misuse terms in MedDRA Drug Information Association www.diahome.org 14 7

Misuse MTS:PTC 3.16.1 Misuse Within MedDRA, misuse is the intentional and inappropriate use of a product (Over-thecounter or prescription) Other than as prescribed or not in accordance with the authorized product information Drug Information Association www.diahome.org 15 Abuse Terms in MedDRA (1) Current Abuse terms in MedDRA 16 8

Abuse Terms in MedDRA (2) Drug Information Association www.diahome.org 17 Abuse MTS:PTC 3.16.2 Abuse Within MedDRA, abuse is the intentional, nontherapeutic use of a product (over-the counter or prescription) For a perceived reward or desired non-therapeutic effect including (e.g., getting high ) Abuse may occur with a single use, sporadic use or persistent use Drug Information Association www.diahome.org 18 9

Addiction MTS:PTC (1) 3.16.3 Addiction Within MedDRA, addiction is an overwhelming desire to take a drug for non-therapeutic purposes together with inability to control or stop its use despite harmful consequences. Addiction can occur because drug induces physical dependence Addiction can occur because of a desire to experience the drug's psychological, behavioral or physical effects. Drug Information Association www.diahome.org 19 Addiction MTS:PTC (2) Example from PTC Drug Information Association www.diahome.org 20 10

Expansion of Medication Error Terms Prior to MedDRA Version 8.0, only one term existed - PT Medication error Medication error section expanded in v8.0 Added HLGT Medication errors in SOC Injury, poisoning and procedural complications HLT Maladministrations HLT Medication errors due to accidental exposures HLT Medication monitoring errors HLT Overdoses HLT Medication errors NEC Drug Information Association www.diahome.org 21 Concept Descriptions Appendix B in MedDRA Introductory Guide To assist in understanding and appropriate use of medication error and product quality issue terms in regulatory reporting Drug Information Association www.diahome.org 22 11

Medication Error Concept Description Example Documented hypersensitivity to administered drug: This medication error refers to the situation when a patient is administered a drug that is documented in the patient's medical file to cause a hypersensitivity reaction in the patient. Example: Despite the fact that the patient's medical record indicated "sulfa allergy," the physician prescribed a sulfa antibiotic. Subsequently, the patient took the antibiotic and experienced hives. Drug Information Association www.diahome.org 23 Medication Errors Terms in MedDRA Approx. 160 LLTs under HLGT Medication errors - Examples LLT Intramuscular formulation administered by other route LLT Wrong drug dispensed Note: Includes overdose terms Drug Information Association www.diahome.org 24 12

Medication Errors MTS:PTC (2) 3.15.1 Medication/Administration Errors 3.15.1.1 Medication errors reported with clinical consequences 3.15.1.2 Medication errors and potential medication errors reported without clinical consequences 3.15.1.3 Medication errors in the context of labeled interactions 3.15.1.4 Do not infer a medication error Drug Information Association www.diahome.org 25 Medication Errors and Product Quality Issues There can be overlap between product quality issues and medication errors An example of both a product quality issue and a medication error is provided Drug Information Association www.diahome.org 26 13

Occupational Exposure Terms in MedDRA Current Occupational Exposure terms in MedDRA Drug Information Association www.diahome.org 27 Occupational Exposures MTS:PTC (1) 3.15.2 Accidental exposures and occupational exposures Within MedDRA, occupational exposure encompasses the chronic exposure to an agent during the normal course of one s occupation Can include additional scenarios in specific regulatory regions Occupational exposure may additionally relate to a more acute, accidental form of exposure In some regions, occupational exposure for healthcare workers could be of particular interest. Drug Information Association www.diahome.org 28 14

Occupational Exposures MTS:PTC (2) Example from PTC Drug Information Association www.diahome.org 29 Summary Many changes in PTC document driven by new PV legislation Off label use Overdose Misuse Abuse Medication errors Occupational exposure MedDRA covers most such concepts and can expand as needed through Change Requests MTS:PTC provides definitions and coding examples. Feedback welcome! Drug Information Association www.diahome.org 30 15

Acknowledgement Thanks to Dr. Patricia Mozzicato and Dr. Judy Harrison for their support in developing this presentation Drug Information Association www.diahome.org 31 Thank You 16